profit from every $100 of sales.
$0$100
First Tracks Biotherapeutics
$49.70+3.76% today
+161.6% since Apr 6, 26
1-year low $15.321-year high $49.70
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What First Tracks Biotherapeutics sold, what it kept, and what it did with the cash.
Sales went from $0 in 2023 to $0 in 2024, with -$164 million of profit last year.
SalesProfit
First Tracks Biotherapeutics vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| First Tracks Biotherapeutics | No profit yet | ||
 Vertex Pharmaceuticals | 35.3× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 21.1× · Fair price | ||
 CSL | 22.2× · Fair price |
AI analysis
An AI analyst reads First Tracks Biotherapeutics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2023 | 2024 |
|---|---|---|
| 0 | 0 | |
| – | – | |
| -118 | -181 | |
| -116 | -179 | |
| -106 | -164 | |
| -3.05 | – | |
| – | – | |
| – | – | |
| – | – |
Balance sheet
| In millions of USD | 2023 | 2024 |
|---|---|---|
| Total assets | 444 | 442 |
| Cash | 36 | 123 |
| Total debt | 18 | 16 |
| Total liabilities | 34 | 50 |
| 410 | 392 | |
| 35 | – | |
| -21.9% | -35.1% | |
| -25.9% | -41.8% |
Cash flow
| In millions of USD | 2023 | 2024 |
|---|---|---|
| -93 | -126 | |
| 1 | 0 | |
| -94 | -126 | |
| Dividends paid | – | – |
| – | – | |
| 18 | 27 |
Valuation
- –
- –
- –
- 0.0×
- –
- –
- –
- -6.0%
- -7.8%
- 0.0%
Profitability
- 0.0%
- 0.0%
- 0.0%
- 0.0%
- -44.4%
- -32.5%
- -40.9%
- -37.0%
- -44.6%
- –
Growth
- –
- –
- −34.5%
- –
- –
Financial health
- 0.6×
- 0.04
- 3.6%
- –
- 10.78
- 10.78
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 10%of 948
Bottom 21%of 871
Bottom 17%of 985
News
Hf Foods signals 3- to 5-year cross-selling runway as Searay adds mid-teens EBITDA margin in first monthSeeking Alpha · Nov 10, 2026Fervo Energy soars as Cape Station's first GeoBlock enters commercial operationSeeking Alpha · Nov 9, 2026Stocks are moving in sync again for the first time in a while. There’s just one problem.MarketWatch · Nov 8, 2026After the Midterm Rally, the Dow Is on Track to Beat the Nasdaq for the First Time Since 2022. Here's What History Says Could Come Next.Yahoo Finance · Nov 6, 2026A record number of first-time home buyers now pay in cash. Here’s where they get the money.MarketWatch · Nov 5, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
32No pass
Benjamin Graham
73Pass
Philip Fisher
37No pass
Peter Lynch
59No pass
Joel Greenblatt
0No pass
Charlie Munger
30No pass
Terry Smith
28No pass
Questions about First Tracks Biotherapeutics
Is First Tracks Biotherapeutics a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the First Tracks Biotherapeutics AI analysis
What does First Tracks Biotherapeutics do?
First Tracks Biotherapeutics, Inc. engages in the research and development of immunology therapeutics for autoimmune and inflammatory diseases. It focuses on clinical-stage programs for rosnilimab, ANB033 and ANB101. The company is headquartered in San Diego, CA. It is in Biotechnology.
Does First Tracks Biotherapeutics pay a dividend?
No. First Tracks Biotherapeutics does not pay a dividend at the moment.
Is First Tracks Biotherapeutics stock halal?
Yes. First Tracks Biotherapeutics passes our halal screen: its business is permitted and its debt is 0.8% of its market value, under the 30% limit. How we check
Who are First Tracks Biotherapeutics's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with First Tracks Biotherapeutics's.
Prices: daily closes to Nov 9, 2026. Fundamentals: company reports via invest-like data.